Drug intelligence / Profile preview

Efthalia

Development stage: Preclinical
Lead developer: MicroCrispr
Modality: Stem Cell Therapies → Cell Therapies

Overview

Efthalia is an allogeneic, ex vivo stem cell-derived insulin-producing beta cell therapy being developed by MicroCrispr for the treatment of Type 1 diabetes. The therapy is designed to replace the function of pancreatic beta cells that are lost or destroyed in patients with the disease, thereby restoring endogenous insulin production and improving glycemic control. Efthalia is currently in the preclinical stage of development.

Beyond the preview

Go deeper on Efthalia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Efthalia.

Explore the full profile